PB2021: QUALITY OF LIFE AND CLINICAL OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH IXAZOMIB‐LENALIDOMIDE‐DEXAMETHASONE (IRD): RESULTS OF A REAL‐WORLD EVIDENCE STUDY
Ionova, T., Vinogradova, O., Kochkareva, Y., Ado, E., Kaplanov, K., Shirokova, M., Shelekhova, T., Levanov, A., Kopylova, A., Li, O., Mitina, T., Rukavitsyn, O., Simashova, P., Anchukova, L., Babich, E., Dasheeva, D., Demchenkova, M., Dubov, S., Esenina, T., Ivanova, L., Kravchuk, T., Rimashevskaya, E., Saraeva, N., Savinova, M., Volkova, S., Porfirieva, N., Nikitina, T.
Published in HemaSphere (23.06.2022)
Published in HemaSphere (23.06.2022)
Get full text
Journal Article
902P Quality of life and response to treatment with ixazomib-lenalidomide-dexamethasone (IRd) in patients with relapsed/refractory multiple myeloma (RRMM) in a real-world setting
Ionova, T., Anchukova, L., Dubov, S., Esenina, T., Ivanova, L., Kaplanov, K., Kochkareva, Y., Kopylova, A., Kravchuk, T., Levanov, A., Li, O., Nikitina, T.P., Rukavitsyn, O., Saraeva, N., Savinova, M., Shelekhova, T., Simashova, P., Shirokova, M., Vinogradova, O., Volkova, S.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article